Mylan loses Pfizer polypeptide patent opposition | ippromagazine.com  IPPro Magazine

Mylan New Zealand’s opposition against a Pfizer Ireland patent has been rejected following a review by the Intellectual Property Office of New Zealand (IPONZ).